Angiotensin Production by the Heart

Kats, Jorge P. van; Danser, A.H. Jan; Meegen, Jan R. van; Sassen, L. M. A.; Verdouw, Pieter D.; Schalekamp, M. A. D. H.

doi:10.1161/01.cir.98.1.73

Cited by 157 publications

(41 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ventricles were immediately frozen in liquid nitrogen. Angiotensin peptides were extracted from plasma and tissue (13,20) and assayed for Ang II or fsAng II by radioimmunoassay (21). The antiserum displayed 75-85% cross-reactivity with fsAng II and 100% with the Ang II metabo-lites Ang III and Ang IV (Ang-(2-8) and Ang-(3-8), respectively).…”

Section: Construction Of Expression Vectors and Production Of Transgenicmentioning

confidence: 99%

“…The antiserum displayed 75-85% cross-reactivity with fsAng II and 100% with the Ang II metabo-lites Ang III and Ang IV (Ang-(2-8) and Ang-(3-8), respectively). Active plasma renin concentration was determined in plasma using an enzyme kinetic assay for Ang I generation in the presence of excess sheep renin substrate (20).…”

Section: Construction Of Expression Vectors and Production Of Transgenicmentioning

confidence: 99%

“…Competitive binding assays were performed by using increasing concentrations ( High Performance Liquid Chromatography of Plasma and Tissue Extracts-Extracts from plasma or cardiac tissue were injected with a tracer amount of 125 I-Ang II on a reversed-phase HPLC system using a Bondapak C18 steel column of 150 ϫ 3.9 mm with a 10-M particle size (Waters, Milford, MA). Angiotensin peptides were separated according to a modification of a protocol described previously (20). As a reference for retention times for fsAng II, Ang II, and its metabolites Ang III and IV (all from Bachem, Torrance, CA), 200 -300 pg of each peptide was injected separately with a tracer amount of 125 I-Ang II.…”

Section: Construction Of Expression Vectors and Production Of Transgenicmentioning

confidence: 99%

See 2 more Smart Citations

Use of a Biological Peptide Pump to Study Chronic Peptide Hormone Action in Transgenic Mice

Kats

Methot

Paradis

et al. 2001

Journal of Biological Chemistry

Self Cite

View full text Add to dashboard Cite

Angiotensin II is a peptide hormone regulator of blood pressure and fluid balance in mammals. Evidence obtained largely in vitro has also suggested that angiotensin II has growth-promoting effects and that it might thereby contribute to such pathological phenomena as cardiac hypertrophy, a major risk factor for cardiovascular mortality. It has been difficult to test for the direct growth-promoting effects of angiotensin II in vivo, however, because of the generalized effects of the peptide on hemodynamics. To overcome this limitation and to test for cardiac-specific functions of angiotensin II, we generated transgenic mice expressing an angiotensin IIproducing fusion protein exclusively in cardiac myocytes. Our findings are the first to distinguish between local and systemic effects of angiotensin II on the heart and introduce a novel technique for studying tissuespecific peptide function.

show abstract

Section: Construction Of Expression Vectors and Production Of Transgenicmentioning

confidence: 99%

Section: Construction Of Expression Vectors and Production Of Transgenicmentioning

confidence: 99%

Section: Construction Of Expression Vectors and Production Of Transgenicmentioning

confidence: 99%

See 1 more Smart Citation

Use of a Biological Peptide Pump to Study Chronic Peptide Hormone Action in Transgenic Mice

Kats

Methot

Paradis

et al. 2001

Journal of Biological Chemistry

Self Cite

View full text Add to dashboard Cite

show abstract

“…14 In animal models it has been shown that despite adequate ACE inhibition there is still near normal production of angiotensin II, via ACE independent pathways, within the myocardium. 15 It was therefore postulated that block of the renin-angiotensin system at the angiotensin II type 1 receptor level would be more beneficial than ACE inhibition. In a metaanalysis of 17 trials looking at ARB the results showed that when ARB were compared with placebo there was a non-significant trend towards improved survival (p = 0.19) and decreased hospitalisation (p = 0.33) with ARB treatment.…”

Section: Medical Treatmentsmentioning

confidence: 99%

Device based treatment of heart failure

Patwala

Wright

2005

Postgraduate Medical Journal

View full text Add to dashboard Cite

As the population ages and survival from ischaemic heart disease improves, the incidence and prevalence of congestive cardiac failure has increased dramatically. Medical treatments including ACE inhibitors, β blockers, and aldosterone antagonists have improved the outlook for most patients. However, despite optimal medical treatment there is a significant group of patients who continue to suffer poor morbidity and mortality. Device based treatment consisting of implantable cardioverter defibrillators (ICD) and cardiac resynchronisation therapy (CRT) devices offer new modes of treatment to patients with symptomatic heart failure despite optimal medical therapy. ICDs have been shown to reduce mortality in patients with severe heart failure while CRT leads to an improvement in functional class, quality of life scores, physiological measures such as peak vo 2, and reduce hospitalisations. Combination devices, which provide both ICD and CRT functions, have now been seen to provide synergistic benefits in selected patients.

show abstract

“…Most cardiac Ang II results from the conversion of local, rather than circulatory Ang I. 10 The cardiac RAS can regulate Ang II within the heart independently of the systemic RAS.…”

Section: The Heartmentioning

confidence: 99%

Local renin-angiotensin systems and their interactions with extra-adrenal corticosteroid production

MacKenzie

Fraser

Connell

et al. 2002

J Renin Angiotensin Aldosterone Syst

View full text Add to dashboard Cite

Adrenal aldosterone production is regulated by the renin-angiotensin system (RAS). It is now known that several other tissues are capable of extra-adrenal aldosterone biosynthesis and that these tissues can also generate angiotensin II through local RAS. Therefore, the regulation of local aldosterone production by the local RAS is a distinct possibility. In this review, we present evidence for the existence of such systems in the vascular system, heart and brain. We then discuss the possibility of interactions between the RAS and aldosterone synthesis at the local level and speculate on the possible physiological effects of such systems in these tissues.

show abstract

Angiotensin Production by the Heart

Cited by 157 publications

References 43 publications

Use of a Biological Peptide Pump to Study Chronic Peptide Hormone Action in Transgenic Mice

Use of a Biological Peptide Pump to Study Chronic Peptide Hormone Action in Transgenic Mice

Device based treatment of heart failure

Local renin-angiotensin systems and their interactions with extra-adrenal corticosteroid production

Contact Info

Product

Resources

About